Developer docs
API playgroundTry for free, no card

Search company profiles

Ocugen

Full company profile

uuid0000e5d

Namestring
Ocugen
Legal namestring
Ocugen, Inc.
Websiteurl
ocugen.com
Company typeenum
Public
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMalvern, United States
HQ citystring
Malvern
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, modifier gene platform, retinal disease treatments, ophthalmic biologics, inhaled vaccines
Industry4 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Gene Therapy Product Sales
TypeOne Time License
Description

Once approved, Ocugen plans to commercialize its gene therapy products directly in the US market. The company is building commercial capabilities including appointing a Chief Commercial Officer. Pricing is expected to be significantly below multi-million dollar typical gene therapy prices.

marketbeat.com
2Licensing Revenue
TypeLicensing Royalties
Description

Ocugen receives upfront fees, development milestones, sales milestones, and royalties on net sales from regional licensing partners. Deals include Kwangdong Pharmaceutical (Korea) and Roots Pharmaceutical (MENA region).

benzinga.com
3Collaboration Revenue
TypeProfessional Services
Description

Ocugen reports modest collaboration income from partnerships, including revenue from NIAID/NIH for vaccine development programs.

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ocugen develops a modifier gene therapy platform using AAV5 viral vectors to deliver nuclear hormone receptor genes (NR2E3, RORA) to retinal cells. The pipeline includes OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, designed as gene-agnostic, one-time subretinal injection treatments. The company also develops biologic (OCU200) and inhaled vaccine (OCU500/510/520) candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 31% reduction in geographic atrophy lesion growth at medium dose after 12 months (OCU410 Phase 2)
+4 more records
Product overview1 text field

Ocugen is a patient-centric biotechnology company developing gene therapies, biologics, and vaccines. Its modifier gene therapy platform represents its core innovation, delivering breakthrough treatments for inherited retinal diseases. The gene therapy portfolio includes OCU400 (Phase 3 for retinitis pigmentosa), OCU410ST (Phase 2/3 for Stargardt disease), and OCU410 (Phase 2 for geographic atrophy). The biologics pipeline features OCU200 (Phase 1 for diabetic macular edema and wet AMD), while the vaccine pipeline includes OCU500 (COVID-19 inhaled vaccine), OCU510 (quadrivalent flu vaccine), and OCU520 (combination flu/COVID vaccine). The company operates from Malvern, PA, with partnerships including Bharat Biotech and CanSino Biologics.

Product and service7 records
1OCU400 (AAV-hNR2E3)
CategoryGene Therapy
Description

A modifier gene therapy using AAV5 vector delivery of the NR2E3 nuclear hormone receptor gene for retinitis pigmentosa treatment. Designed as a gene-agnostic, one-time subretinal injection therapy targeting multiple genetic mutations causing RP.

2OCU410ST (AAV-hRORA)
CategoryGene Therapy
Description

A modifier gene therapy using AAV5 vector delivery of the RORA gene for Stargardt disease, an orphan inherited retinal disease. Targets ABCA4 gene mutations causing photoreceptor degeneration.

3OCU410 (AAV-hRORA)
CategoryGene Therapy
Description

A modifier gene therapy using AAV5 vector delivery of the RORA gene for geographic atrophy secondary to dry age-related macular degeneration. Targets lipid metabolism, oxidative stress, inflammation, and complement pathways.

4OCU200 (Transferrin-Tumstatin)
CategoryBiologic
Description

A novel fusion protein biologic consisting of tumstatin and transferrin for treating diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. Uses integrin receptor targeting to regress abnormal blood vessels and inhibit neovascularization.

5OCU500
CategoryVaccine
Description

COVID-19 inhaled vaccine based on a chimpanzee adenovirus (ChAd) vector platform designed to reduce transmission with mucosal immunity through inhalation delivery.

6OCU510
CategoryVaccine
Description

Seasonal quadrivalent influenza inhaled vaccine using the ChAd platform designed to elicit both humoral (IgG) and mucosal (IgA) immune responses.

7OCU520
CategoryVaccine
Description

Combination quadrivalent seasonal influenza and COVID-19 inhaled vaccine using the ChAd platform for dual protection against both respiratory diseases.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-08-06
Description

Binding term sheet signed for exclusive license of OCU400 in retinitis pigmentosa across the MENA region, valued at up to $255 million in sales milestones plus a 22% royalty on net sales.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-07-13
Description

Binding term sheet for exclusive license of OCU400 in retinitis pigmentosa covering the Middle East and North Africa region. Ocugen receives upfront fees and development milestones up to $4 million, sales milestone payments up to $255 million, and a 22% royalty on net sales, while manufacturing and supplying commercial product.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2026-07-13
Description

Strategic partner with Roots Pharmaceutical for exclusive license of OCU400 in retinitis pigmentosa across MENA region.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-09-15
Description

Licensing agreement granting exclusive Korean rights to OCU400 for retinitis pigmentosa. Ocugen receives upfront license fees and near-term development milestone payments up to $7.5 million, with potential sales milestones reaching $180 million or more and a 25% royalty on net sales over the first 10 years of commercialization.

5Carisma Therapeutics
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Ocugen's subsidiary OrthoCelix merged with Carisma Therapeutics in an all-stock reverse merger transaction, creating a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. Ocugen shareholders expected to own approximately 90% of combined entity.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of vaccines and bio-therapeutics, and WHO Pre-qualifications. Located in Genome Valley in Hyderabad, India.

Strategic tierCoreTypeTechnology or Integration
Description

CanSino Biologics is an innovative biopharmaceutical company dedicated to vaccine development, manufacturing, and commercialization. Their commitment to quality and scientific expertise around clinical development and manufacturing has made them an important collaborator in Ocugen's modifier gene therapy program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

OCU500 COVID-19 inhaled vaccine was selected by NIH/NIAID Project NextGen for inclusion in clinical trials. NIAID intends to initiate Phase 1 clinical trial for OCU500.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Approved Syfovre for geographic atrophy (complement inhibitor), directly competing with Ocugen's OCU410. Larger, revenue-generating commercial-stage company in overlapping indication.

TypeBroad incumbent
Description

Approved Izervay for geographic atrophy, now part of Astellas. Represents major commercial-stage competitor to Ocugen's OCU410 in the GA indication with established market presence.

TypeEmerging player
Description

Clinical-stage genome editing company with ophthalmology programs (EDIT-101 for LCA10) targeting inherited retinal diseases. Represents an alternative technology approach (CRISPR vs. AAV gene replacement) competing for similar patient populations.

TypeDirect peer
Description

AAV gene therapy developer with multiple ophthalmology programs (RGX-314 for wet AMD) and proprietary NAV technology platform. Closely comparable to Ocugen given shared AAV-based approach to retinal diseases and similar pipeline stage profile.

TypeDirect peer
Description

Clinical-stage gene therapy company with leading ophthalmology programs (AAV-RPGR for RP, AAV-CNGB3 and AAV-CNGA3 for achromatopsia). Directly competes with Ocugen in inherited retinal disease space with similar modality.

TypeBroad incumbent
Description

AAV-based gene therapy company with approved Hemgenix for hemophilia B and pipeline across multiple indications. Comparable as a gene therapy platform company with similar manufacturing and regulatory challenges to Ocugen.

TypeBroad incumbent
Description

Pioneer in ophthalmology gene therapy (approved Luxturna for RPE65-mediated retinal dystrophy); now part of Roche. Sets commercial benchmark for retinal gene therapy pricing and access, and competes with Ocugen's OCU400 in adjacent RP patient populations.

TypeDirect peer
Description

Clinical-stage gene therapy company targeting retinal diseases (Lumevoq for Leber hereditary optic neuropathy, GS030 for RP). Similar platform technology and ophthalmology focus to Ocugen, with comparable stage and European market orientation.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on ocular diseases (wet AMD, diabetic macular edema) using AAV vectors. Directly comparable to Ocugen given overlapping retinal indications and AAV platform approach.

TypeDirect peer
Description

Commercial-stage gene therapy company (Vyjuvek for dystrophic epidermolysis bullosa) using HSV-based delivery platform with similar patient-centric rare disease commercial model. Comparable in size, stage, and gene therapy commercialization approach to Ocugen.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ocugen

Gene Therapyocugen.com

Ocugen firmographics

Firmographics
Name
Ocugen
Legal name
Ocugen, Inc.
Website
https://ocugen.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Ocugen industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Gene therapy development
  • Modifier gene platform
  • Retinal disease treatments
  • Ophthalmic biologics
  • Inhaled vaccines

Where Ocugen is headquartered

Location

Headquarters

HQ city
Malvern
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Ocugen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Gene Therapy Product Sales: Once approved, Ocugen plans to commercialize its gene therapy products directly in the US market. The company is building commercial capabilities including appointing a Chief Commercial Officer. Pricing is expected to be significantly below multi-million dollar typical gene therapy prices.
  2. Licensing Revenue: Ocugen receives upfront fees, development milestones, sales milestones, and royalties on net sales from regional licensing partners. Deals include Kwangdong Pharmaceutical (Korea) and Roots Pharmaceutical (MENA region).
  3. Collaboration Revenue: Ocugen reports modest collaboration income from partnerships, including revenue from NIAID/NIH for vaccine development programs.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Ocugen product offering

Product offering

Core offering

Ocugen develops a modifier gene therapy platform using AAV5 viral vectors to deliver nuclear hormone receptor genes (NR2E3, RORA) to retinal cells. The pipeline includes OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, designed as gene-agnostic, one-time subretinal injection treatments. The company also develops biologic (OCU200) and inhaled vaccine (OCU500/510/520) candidates.

Product overview

Ocugen is a patient-centric biotechnology company developing gene therapies, biologics, and vaccines. Its modifier gene therapy platform represents its core innovation, delivering breakthrough treatments for inherited retinal diseases. The gene therapy portfolio includes OCU400 (Phase 3 for retinitis pigmentosa), OCU410ST (Phase 2/3 for Stargardt disease), and OCU410 (Phase 2 for geographic atrophy). The biologics pipeline features OCU200 (Phase 1 for diabetic macular edema and wet AMD), while the vaccine pipeline includes OCU500 (COVID-19 inhaled vaccine), OCU510 (quadrivalent flu vaccine), and OCU520 (combination flu/COVID vaccine). The company operates from Malvern, PA, with partnerships including Bharat Biotech and CanSino Biologics.

Differentiator

Problem solved

Functional benefit

Products and services

  • OCU400 (AAV-hNR2E3) A modifier gene therapy using AAV5 vector delivery of the NR2E3 nuclear hormone receptor gene for retinitis pigmentosa treatment. Designed as a gene-agnostic, one-time subretinal injection therapy targeting multiple genetic mutations causing RP.
  • OCU410ST (AAV-hRORA) A modifier gene therapy using AAV5 vector delivery of the RORA gene for Stargardt disease, an orphan inherited retinal disease. Targets ABCA4 gene mutations causing photoreceptor degeneration.
  • OCU410 (AAV-hRORA) A modifier gene therapy using AAV5 vector delivery of the RORA gene for geographic atrophy secondary to dry age-related macular degeneration. Targets lipid metabolism, oxidative stress, inflammation, and complement pathways.
  • OCU200 (Transferrin-Tumstatin) A novel fusion protein biologic consisting of tumstatin and transferrin for treating diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. Uses integrin receptor targeting to regress abnormal blood vessels and inhibit neovascularization.
  • OCU500 COVID-19 inhaled vaccine based on a chimpanzee adenovirus (ChAd) vector platform designed to reduce transmission with mucosal immunity through inhalation delivery.
  • OCU510 Seasonal quadrivalent influenza inhaled vaccine using the ChAd platform designed to elicit both humoral (IgG) and mucosal (IgA) immune responses.
  • OCU520 Combination quadrivalent seasonal influenza and COVID-19 inhaled vaccine using the ChAd platform for dual protection against both respiratory diseases.

Quantifiable outcome

  • 31% reduction in geographic atrophy lesion growth at medium dose after 12 months (OCU410 Phase 2)
  • +4 more outcomes

Companies that use Ocugen

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Ocugen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ocugen partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Roots Pharmaceutical and Al-Dhow International HoldingcoreGTM or Marketing Partner · 6 August 2026Binding term sheet signed for exclusive license of OCU400 in retinitis pigmentosa across the MENA region, valued at up to $255 million in sales milestones plus a 22% royalty on net sales.
  • Roots PharmaceuticalcoreGTM or Marketing Partner · 13 July 2026Binding term sheet for exclusive license of OCU400 in retinitis pigmentosa covering the Middle East and North Africa region. Ocugen receives upfront fees and development milestones up to $4 million, sales milestone payments up to $255 million, and a 22% royalty on net sales, while manufacturing and supplying commercial product.
  • Al-Dhow International HoldingcoreGTM or Marketing Partner · 13 July 2026Strategic partner with Roots Pharmaceutical for exclusive license of OCU400 in retinitis pigmentosa across MENA region.
  • Kwangdong PharmaceuticalcoreGTM or Marketing Partner · 15 September 2025Licensing agreement granting exclusive Korean rights to OCU400 for retinitis pigmentosa. Ocugen receives upfront license fees and near-term development milestone payments up to $7.5 million, with potential sales milestones reaching $180 million or more and a 25% royalty on net sales over the first 10 years of commercialization.
  • Carisma TherapeuticsminorStrategic or Co-development Partner · 23 June 2025Ocugen's subsidiary OrthoCelix merged with Carisma Therapeutics in an all-stock reverse merger transaction, creating a Nasdaq-listed company focused on regenerative cell therapies for orthopedic diseases. Ocugen shareholders expected to own approximately 90% of combined entity.
  • Bharat BiotechcoreStrategic or Co-development PartnerBharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of vaccines and bio-therapeutics, and WHO Pre-qualifications. Located in Genome Valley in Hyderabad, India.
  • CanSino BiologicscoreTechnology or IntegrationCanSino Biologics is an innovative biopharmaceutical company dedicated to vaccine development, manufacturing, and commercialization. Their commitment to quality and scientific expertise around clinical development and manufacturing has made them an important collaborator in Ocugen's modifier gene therapy program.
  • NIH/NIAIDcoreStrategic or Co-development PartnerOCU500 COVID-19 inhaled vaccine was selected by NIH/NIAID Project NextGen for inclusion in clinical trials. NIAID intends to initiate Phase 1 clinical trial for OCU500.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Ocugen competitors and assessment

Company assessment

Broad incumbents

  • Apellis Pharmaceuticals: Approved Syfovre for geographic atrophy (complement inhibitor), directly competing with Ocugen's OCU410. Larger, revenue-generating commercial-stage company in overlapping indication.
  • Iveric Bio (Astellas): Approved Izervay for geographic atrophy, now part of Astellas. Represents major commercial-stage competitor to Ocugen's OCU410 in the GA indication with established market presence.
  • uniQure: AAV-based gene therapy company with approved Hemgenix for hemophilia B and pipeline across multiple indications. Comparable as a gene therapy platform company with similar manufacturing and regulatory challenges to Ocugen.
  • Spark Therapeutics (Roche): Pioneer in ophthalmology gene therapy (approved Luxturna for RPE65-mediated retinal dystrophy); now part of Roche. Sets commercial benchmark for retinal gene therapy pricing and access, and competes with Ocugen's OCU400 in adjacent RP patient populations.

Emerging players

  • Editas Medicine: Clinical-stage genome editing company with ophthalmology programs (EDIT-101 for LCA10) targeting inherited retinal diseases. Represents an alternative technology approach (CRISPR vs. AAV gene replacement) competing for similar patient populations.

Direct peers

  • REGENXBIO: AAV gene therapy developer with multiple ophthalmology programs (RGX-314 for wet AMD) and proprietary NAV technology platform. Closely comparable to Ocugen given shared AAV-based approach to retinal diseases and similar pipeline stage profile.
  • MeiraGTx: Clinical-stage gene therapy company with leading ophthalmology programs (AAV-RPGR for RP, AAV-CNGB3 and AAV-CNGA3 for achromatopsia). Directly competes with Ocugen in inherited retinal disease space with similar modality.
  • GenSight Biologics: Clinical-stage gene therapy company targeting retinal diseases (Lumevoq for Leber hereditary optic neuropathy, GS030 for RP). Similar platform technology and ophthalmology focus to Ocugen, with comparable stage and European market orientation.
  • Adverum Biotechnologies: Clinical-stage gene therapy company focused on ocular diseases (wet AMD, diabetic macular edema) using AAV vectors. Directly comparable to Ocugen given overlapping retinal indications and AAV platform approach.
  • Krystal Biotech: Commercial-stage gene therapy company (Vyjuvek for dystrophic epidermolysis bullosa) using HSV-based delivery platform with similar patient-centric rare disease commercial model. Comparable in size, stage, and gene therapy commercialization approach to Ocugen.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ocugen social profiles

Digital presence

Ocugen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ocugen leadership team

Management profile

Number of profiles

Profiles13 records

Ocugen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Ocugen funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ocugen M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ocugen

What does Ocugen do?

Ocugen develops a modifier gene therapy platform using AAV5 viral vectors to deliver nuclear hormone receptor genes (NR2E3, RORA) to retinal cells. The pipeline includes OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy, designed as gene-agnostic, one-time subretinal injection treatments. The company also develops biologic (OCU200) and inhaled vaccine (OCU500/510/520) candidates.

Is Ocugen a public or private company?

Ocugen is a public company. It is classified as public and is currently operating.

When was Ocugen founded?

Ocugen was founded in 2013. It employs 101 to 250 people.

Where is Ocugen based?

Ocugen is headquartered in Malvern, United States, in the North America region.

How does Ocugen make money?

Three revenue lines are on record. Gene Therapy Product Sales are the primary driver. The others are licensing Revenue and collaboration Revenue.

Who are Ocugen's main competitors?

Broad incumbents on record are Apellis Pharmaceuticals, Iveric Bio (Astellas), uniQure and Spark Therapeutics (Roche). Editas Medicine is listed as an emerging player. Direct peers are REGENXBIO, MeiraGTx, GenSight Biologics, Adverum Biotechnologies and Krystal Biotech.

Does Ocugen have an API?

No public API is recorded for Ocugen.

What industry is Ocugen in?

Ocugen's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchOcugen Inc. stock falls Tuesday, underperforms marketOcugen Inc. shares fell 2.11% to $0.76 on Tuesday, marking the fourth consecutive day of losses. The decline occurred amid a broader market downturn, with the S&P 500 down 1.03% and the Dow down 1.64%.MarketWatchOcugen Inc. stock falls Monday, underperforms marketOcugen Inc. shares fell 6.62% to $0.77 on Monday, marking a third consecutive day of losses. The decline occurred amid a broader market downturn, with the S&P 500 down 1.92% and the Dow down 1.41%.MarketWatchOcugen Inc. stock falls Friday, underperforms marketOcugen Inc. shares fell 5.24% to $0.83 on Friday, marking a second consecutive day of losses. The stock underperformed a mixed market session where the Dow rose 0.10% and the S&P 500 fell 0.40%.MarketWatchOcugen Inc. stock falls Thursday, underperforms marketOcugen Inc. shares fell 9.04% to $0.87 on Thursday, underperforming the market as the S&P 500 and Dow Jones declined. The stock closed 67.94% below its 52-week high of $2.73, which was reached on March 17th.MarketBeatOcugen Eyes 2027 Trial Results and FDA Filing for Lead Gene TherapyOcugen expects pivotal data for its lead gene therapy for retinitis pigmentosa in Q1 2027, with a potential FDA filing in Q2 2027. The Phase III trial includes 140 patients across ~30 genetic mutations, and the company plans to seek a pre-filing meeting with the FDA. It also has programs for Stargardt disease and geographic atrophy.MarketWatchOcugen Inc. stock rises Wednesday, still underperforms marketOcugen Inc. shares rose 1.09% to $0.96 on Wednesday, with the S&P 500 up 1.31% and the Dow up 0.49%. The stock remains 64.76% below its 52-week high of $2.73, reached on March 17th.MarketWatchOcugen Inc. stock falls Tuesday, underperforms marketOcugen Inc. shares fell 2.27% to $0.95 on Tuesday, ending a two-day winning streak. The decline occurred as the S&P 500 dropped 0.38% to 7,520.93 and the Dow fell 0.30% to 52,231.89.Stock TitanOcugen licenses OCU400 to Celairis for up to $7.1MOcugen and Celairis signed an exclusive license agreement for OCU400, a gene therapy for retinitis pigmentosa, covering Australia, New Zealand, and ASEAN. The deal includes an upfront fee and potential milestone payments totaling up to $7.1 million, plus a 50% share of gross profits. Celairis will handle regional regulatory and commercialization, with top-line data expected in Q1 2027.Quiver QuantitativeLobbying Update: $30,000 of OCUGEN INC. lobbying was just disclosed | OCGN Stock NewsOCUGEN INC. disclosed $30,000 in lobbying spending for Q3 2026, covering health care and innovation issues. Insiders traded the stock five times in six months, with CEO selling 1,051,982 shares. Hedge fund activity shows 76 institutions added shares while 74 reduced positions in Q2 2026.MarketWatchOcugen Inc. stock rises Monday, outperforms marketOcugen Inc. shares rose 5.09% to $0.97 on Monday, marking a second consecutive day of gains. The stock outperformed the market, with the S&P 500 up 2.35% and the Dow up 2.15%.